EDNRA and cancer: In preclinical studies, tezosentan has demonstrated encouraging outcomes in inhibiting the growth of cancer cells and promoting apoptosis, particularly in tumors that exhibit elevated levels of endothelin receptor type A. The mechanism of action of tezosentan involves targeting and inhibiting endothelin receptors, which are known to play a crucial role in cancer development and progression.